Research
INSIGHTS
Deep dives into the science, targets, and market opportunities behind our pipeline.
April 2026
The Case for TNIK + GLP-1 Combination Therapy
How combining TNIK inhibitors with GLP-1 agonists could create the first obesity treatment that preserves muscle mass.
Read →
April 2026
TNIK: The Next Frontier Beyond GLP-1 in Obesity
Why TNIK inhibitors could solve the muscle loss problem that limits current obesity drugs.
Read →
March 2026
TYK2 Case Study: From Zero to Gate A in 14 Days
22,910 variants generated, 5,509 ADMET-passed, Tier 2 structure verification — the full technical breakdown.
Read →